title: Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry.
abstract: BACKGROUND
  The effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention for acute myocardial infarction has been tested in clinical trials, but its use in a real-world scenario has never been reported.
  
  
  METHODS
  From the total number of patients enrolled in the EUROVISION registry, 678 subjects affected by ST-elevation myocardial infarction were selected and included in the analysis. Posology and usage patterns of bivalirudin, as evaluated by dose and time of drug bolus and infusion administered, were evaluated. The 30-day outcome has been assessed by efficacy and safety endpoints.
  
  
  RESULTS
  All patients received an initial intravenous bolus of bivalirudin (0.70±0.25 mg/kg) followed by an infusion (1.58±0.47 mg/kg/h; duration: 60 [30, 107] min) in 99.3% of cases. An additional bolus (0.49±0.06 mg/kg) was administered in 9.3% of patients. Bivalirudin infusion was prolonged after procedure in 62.2%. Death occurred in 2.1% of patients, non-fatal myocardial reinfarction in 0.3%, unplanned revascularization in 0.6% and non-fatal stroke in 0.4%. Acute stent thrombosis was not observed. Major bleeding occurred in 1.5% of patients.
  
  
  CONCLUSIONS
  Bivalirudin usage in the setting of primary PCI provided excellent results in terms of 30-day outcome even in a real-world population.
authors.affiliation: Misericordia Hospital , ASL 9 Grosseto , Italy.
authors.forename: U
authors.initials: U
authors.lastname: Limbruno
authors.forename: A
authors.initials: A
authors.lastname: Picchi
authors.forename: S
authors.initials: S
authors.lastname: Galli
authors.forename: K
authors.initials: K
authors.lastname: Huber
authors.forename: J
authors.initials: J
authors.lastname: Lipiecki
authors.forename: D
authors.initials: D
authors.lastname: Bernstein
authors.forename: E
authors.initials: E
authors.lastname: Deliargyris
authors.forename: P
authors.initials: P
authors.lastname: Anthopoulos
authors.forename: C
authors.initials: C
authors.lastname: Nienaber
authors.forename: M
authors.initials: M
authors.lastname: Hamon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005060:Europe; D005260:Female; D006629:Hirudins / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012042:Registries; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin
keywords: Antithrombotic therapy; ST-elevation myocardial infarction; primary percutaneous coronary intervention